CRL

Charles River Laboratories International, Inc.

Charles River Laboratories International Inc is a pharmaceutical company providing drug discovery and development services. The company provides animal models for laboratory testing, and offers manufacturing testing services to various industries.

Charles River Laboratories International, Inc. (CRL) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A); its weakest is Value (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
D+
Factor Score 1.8 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
A
Factor Score 4.2 / 5.0
Revisions
B
Factor Score 3.4 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 367.4
EV / EBITDA 20.8
Rev Growth YoY -2.2%
Gross Margin 35.1%
Price Return 3M 17.9%
Price Return 12M 97.1%
Catalyst Signal +0.28
Market Cap $16.2B
TTM Revenue $4.0B
Price / Sales 4.1
ROE 1.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 D+ (1.8) C- (2.0) C+ (2.8) A (4.2) B (3.4) C+ (2.8)
2026-11-09 D+ (1.8) C- (2.0) C+ (2.8) A (4.2) B (3.4) C+ (2.8)
2026-11-06 C+ (2.7) C- (2.0) C+ (2.7) A+ (4.5) A+ (4.5) B (3.3)
2026-11-05 C+ (2.7) C- (2.0) C+ (2.7) A+ (4.5) A+ (4.6) B (3.3)
2026-11-04 C+ (2.7) C- (2.0) C+ (2.7) A (4.5) A (4.3) B (3.2)
Page 1 of 10
…